Related by context. All words. (Click for frequent words.) 65 Eluting Stent 64 Oral Fingolimod 63 By JENNIFER LEARN 62 somatostatin analog 62 EURIDIS 62 Randomized Phase II 62 Controlled Trial 62 Hsp# Inhibitor 61 multicenter randomized Phase III 61 Multicenter 61 Randomized Evaluation 61 TMC# C# 61 Combination REOLYSIN R 61 registrational Phase 61 Novel Oral 61 Clinical Trial Results 61 Randomized Phase 61 Pharmacodynamics 61 Sorafenib HCC Assessment 61 NCIC CTG 61 Clinical Outcome 61 ExTRACT TIMI 61 Prospective Randomized 60 J Am Acad 60 Proc Am Soc 60 Prospective Multicenter 60 Phase III multicenter 60 methylnaltrexone bromide 60 multicenter phase 60 J Am Coll 60 Prolongs Survival 60 Randomized Double Blind Placebo 60 Dose Ranging Study 60 multicenter placebo controlled 60 Crit Rev 60 Intervention Effectiveness 60 MIVI III 60 Acute Ischemic Stroke 60 Completes Patient Enrollment 60 TM Drug Eluting 59 Antigen Specific 59 J Clin Endocrinol Metab 59 Multicenter Phase 59 Randomized Double blind 59 #:#-# [029] 59 Phase III Clinical Trial 59 Controlled Study 59 Initiated Phase 59 multicenter randomized controlled 59 multicenter Phase III 59 Orally Active 59 Myocardial Infarction Study 59 cathepsin K inhibitor 59 Trandolapril 59 Randomised 59 novel VDA molecule 59 Single Dose 59 Tanespimycin 59 Study Evaluating 59 EMBO J. 59 Randomized Double Blind 59 Tocopherol 58 See CLINICAL PHARMACOLOGY 58 Long Term Efficacy 58 Randomized Study 58 J Clin 58 Multicenter Randomized 58 Inflammatory Arthritis 58 Antitumor 58 EXPLORE Xa 58 ADVANCE PD 58 Double Blind Placebo 58 NSABP B 58 CLARITY TIMI 58 TAXUS ATLAS 58 multicenter prospective 58 azilsartan medoxomil 58 Intravascular 58 Asthma Intervention 58 multicenter Phase II 58 #:#-# [020] 58 multicentre randomized 58 Pivotal Phase 58 pan HDAC inhibitor 58 Phase 2a Trial 58 J Consult Clin 58 Antiviral Therapy 58 Meta Analysis 58 Pooled Analysis 58 Severe Sepsis 58 RELOVAIR ™ 58 PREOS R 58 Randomized Clinical Trials 58 Phase 2b Clinical Trial 58 plus Copegus R 58 Initiate Phase 58 Randomized Clinical Trial 58 #-# Full Text 58 Meets Primary Endpoint 58 Eur J 58 Glufosfamide 58 Shows Promise Against 58 Clinical Antipsychotic Trials 57 vapreotide acetate 57 Phase IIIb 57 Long Lesion 57 Randomized controlled 57 Placebo Controlled 57 Val HeFT 57 J Nutr 57 #:#-# [035] 57 Cypher Sirolimus 57 lexidronam injection 57 Transdermal Patch 57 #:#-# [023] 57 Recombinant Human 57 Efficacy Trial 57 TRANSDUR ™ 57 Neuroendocrine Tumors 57 #:#-# [001] 57 Int J Obes Relat 57 PROTEGE 57 Intervention Trial GAIT 57 Attenuates 57 Placebo Controlled Trial 57 THAT ARE DIFFICULT TO 57 SANTE 57 International Verapamil SR 57 Cardiol 57 Kinase Inhibitor 57 TM +#:#.# 57 Antiviral Activity 57 Nat Clin Pract 57 designated HVTN 57 dose escalation clinical 57 Pivotal Trial 57 pharmacokinetic PK study 57 CYP#A# CYP#D# 57 Prostate AdenoCarcinoma Treatment 57 Ranolazine 57 ASTEROID 57 hyperphenylalaninemia HPA due 57 Radiofrequency Ablation 57 doi #.#/j.#-#.#.#.x 57 mGluR5 negative 57 Pharmacokinetic Study 57 Phase 2a Clinical Trial 57 Gastric Cancer 57 Am J Obstet 57 Relapsing Multiple Sclerosis 57 Suppl. 57 J Am Soc 57 SE5 OH containing 57 Ceflatonin R 57 MEND CABG 56 Hormone Refractory Prostate Cancer 56 Pulmonary Arterial Hypertension 56 Phase 2b Study 56 RAVEL 56 Am J Clin 56 J Allergy Clin 56 multicentre randomized controlled 56 evaluating tivozanib 56 Subgroup Analysis 56 antibody blinatumomab MT#/MEDI-# 56 Phase IIb Trial 56 Endocrinol 56 Myelodysplastic Syndrome MDS 56 Pathol 56 interferon gamma 1b 56 Drug Eluting Stent System 56 Safinamide 56 placebo controlled Phase III 56 Diabet Med 56 phase IIIb 56 Cancer Res 56 arsenic trioxide injection 56 Transdermal Delivery 56 Eur Arch 56 multicenter randomized placebo controlled 56 bepotastine besilate nasal spray 56 Zorbtive TM 56 Intravitreal 56 Annu Rev 56 STRIDE PD 56 Diabetic Nephropathy 56 MKC# MKC# PP 56 Clin Oncol 56 multicenter Phase 56 Antitumor Activity 56 Thromb Haemost 56 ALN HPN 56 Phase IIb III 56 Vascugel 56 PEGylated anti 56 #:#-# [031] 56 AIR2 Trial 56 Nephrol 56 J Child Adolesc 56 Kahalalide F 56 APEX PD 56 Tipranavir 56 YONDELIS 56 II Clinical Trial 56 FDA APPROVES 56 CHAMPION PCI 56 Aneurysm Repair 56 Degarelix 56 Acta Paediatr 56 Double Blind Randomized 56 familial amyloidotic polyneuropathy FAP 56 Pivotal Study 56 TNF Tumor Necrosis Factor 56 Randomized Controlled Trials 56 Parathyroid Hormone 56 Drug Eluting 56 CrossRef Medline 56 Curr Opin 56 Phase Ib II 56 Tezampanel 56 Mycophenolate Mofetil 56 Polyp Prevention Trial 56 RE LY 56 Hepatocellular Carcinoma 56 Immunotherapeutic 56 Alzheimer Disease Cooperative 56 V Everolimus Eluting Coronary 56 fosbretabulin 56 J Cereb Blood 56 SUTENT ® 56 #:#-# [028] 56 Postmenopausal Hormone Therapy 56 Ann Oncol 56 Biomarker Study 56 Antiplatelet 56 doi #.# 56 Vitro Activity 56 Granted Orphan Drug 56 PSMA ADC 56 Pivotal Phase III 55 Geochimica et Cosmochimica Acta 55 Oligonucleotides 55 CALERIE 55 FASEB J. 55 GOUT 55 Sirolimus eluting Coronary Stent 55 Chronic Heart Failure 55 Cardiac Resynchronization Therapy 55 Preclinical Study 55 DAPT Study 55 NO# [002] 55 Postdoctoral Position 55 humanized monoclonal 55 Trial Evaluating 55 Ziprasidone 55 R lenalidomide 55 Autologous Stem Cell Transplantation 55 Safety Tolerability 55 prospective randomized multicenter 55 bevacizumab Avastin R 55 Psychiatry Clin Neurosci 55 Carotid Revascularization Endarterectomy vs. 55 TM Everolimus Eluting 55 Completes Enrollment 55 Hematological 55 Medidur TM FA 55 paclitaxel poliglumex 55 First Patient Dosed 55 Febuxostat 55 Nucleic Acids Res 55 ENDEAVOR IV 55 double blinded randomized 55 Nuclear Receptors 55 Left Ventricular 55 Carotid 55 J Clin Oncol 55 #:#-# [007] 55 pegylated recombinant 55 Hepatotoxicity 55 Deforolimus 55 Ann Pharmacother 55 ritonavir boosted 55 Deutsches Symphonie Orchester 55 REFLEX 55 Yamaha +#:#.# 55 kidney urologic 55 Cell Mol Physiol 55 ENESTnd 55 multicenter multinational 55 R Saizen R 55 Syndr 55 #:#-# [025] 55 Pharmacokinetics PK 55 LUX Lung 55 Phase III Trial 55 liposomal formulation 55 Renal Transplantation 55 RECORD1 55 Centre de Recherche 55 selective orally bioavailable 55 Demonstrates Sustained 55 Arch Neurol 55 Treating Chronic 55 Neurol 55 cisplatin gemcitabine 55 FOLOTYN ® 55 Dabigatran etexilate 55 Shows Promising 55 multicentre 55 Molecular Cancer 55 Anti CD# Antibody 55 placebo controlled clinical 55 number NCT# ClinicalTrials.gov 55 ABSORB clinical 55 Heart Circ Physiol 55 것이다 55 PRECISE 55 Edge STudy 55 Chronic Hepatitis C 55 Nat Genet 55 EuroIntervention 55 ARCALYST ® rilonacept 55 Phase IIIb clinical 55 Aflibercept 55 #:#-# [030] 55 Mol Cell 55 Psychosom Med 55 Free Full Text 55 ODT metoclopramide HCl PEPCID 55 Hum Mol Genet 55 Protein Expression 55 phase IIb clinical 55 #:#-# [019] 54 Abstract Free Full Text 54 Neurochemistry 54 Intervention Effectiveness CATIE 54 Hesperion XXI 54 Immunogenicity 54 Diabetologia 54 Xelox 54 Cardiac Allograft Rejection 54 TRA 2P 54 Systemic Sclerosis 54 refractory chronic lymphocytic 54 HCV SPRINT 54 multicenter randomized double 54 Liposomal 54 landmark ATHENA 54 Amino Acid 54 CALGB # [002] 54 Aortic Stenosis 54 Toxicol 54 Effectively Treats 54 ADONIS 54 Phase III psoriasis 54 · 说 54 Vaccine Adjuvants 54 Antithrombin 54 SM Transfer Compartment 54 Stent Restenosis 54 Bone Metastases 54 Cosimo Cutri 54 Int J 54 RE MODEL 54 randomized Phase III 54 prospective multicentre 54 ECASS 54 LATEST WRESTLING NEWS 54 Sipuleucel T 54 selective antagonist 54 J Psychopharmacol 54 Advanced Renal Cell 54 multicenter randomized 54 Phase Ib clinical 54 PEG IFN 54 PHASE III 54 Alvesco R 54 Biologie 54 Synta Announces 54 年 考研 54 Acute Decompensated Heart Failure 54 Cell Physiol 54 Inflammatory Markers 54 PROMUS R 54 Pegylated Liposomal Doxorubicin 54 ABLYNX 54 Left Ventricular Dysfunction 54 Study ADCS 54 이다 54 MIST II 54 Aplidin R 54 #:# -# [004] 54 Multicenter Study 54 DUROS 54 로 54 randomized controlled multicenter 54 blinded randomized placebo controlled 54 CYT# potent vascular disrupting 54 Endocrinol Metab 54 q8h 54 #:#-# [040] 54 TRO# 54 Luteinizing Hormone Releasing Hormone 54 TRX1 54 REALITY Trial 54 relapsing multiple sclerosis 54 Phase Ib Clinical Trial 54 Cancer Incidence Mortality 54 Ann Surg 54 RE LY ® 54 édition du 54 PEGylated interferon 54 placebo controlled randomized 54 Novel Method 54 subcutaneously administered 54 Environ Health Perspect 54 Stent Thrombosis 54 DU #b 54 #:#-# [022] 54 #:#-# [037] 54 Phytotherapy Research 54 J Pediatr 54 #:#-# [006] 54 endoluminal stent graft 54 Therapy Improves 54 Chronic Liver Disease 54 complement inhibitor eculizumab 54 AVOREN 54 Molecular Basis 54 J Neurosurg 54 Ischemic 54 Aurora Kinase 54 antibody MAb 54 Cardiotoxicity 54 Neupogen ® 54 suppl. 54 Clin J 54 phase IIa clinical 54 #:#-#,# CrossRef Medline [002] 54 Phase Ib IIa 54 IMPACT IMmunotherapy 54 candesartan cilexetil 54 Nutr 54 severe oral mucositis 54 RU EEU EUROPE ASIA 54 ONTARGET 54 Am J Respir 54 iobenguane 54 IN PATIENTS WITH 54 Transthyretin 54 multicentre randomized double 54 AIR CF2 54 Dendritic Cells 54 Acute Myocardial Infarction 54 Mads Ostberg Adapta WRT 54 #:#-# [033] 54 doi #.#/fj.#-# 54 Systematic Review 54 Dosimetry 54 WRX STi +# mins 54 TO AVOID PREGNANCY WHILE 54 placebo controlled Phase 54 basal bolus regimen 54 CIMZIA ™ 54 phase Ib 54 randomized controlled Phase 54 Psychiatric Services #:#-#,# 54 Clinical Evaluation 54 CEQ# 54 Autoantibodies 54 lanreotide 54 Vertebral Fractures 53 Mol Biol 53 Best Pract Res 53 听力 53 Phase III Clinical Trials 53 Protein Function 53 preclinical efficacy 53 longitudinal observational study 53 vitro pharmacology 53 Intracranial Aneurysms 53 #:#-# [027] 53 INGAP 53 Complicated Skin 53 CAMMS# 53 EMRG VIO 53 J Clin Epidemiol 53 Enzastaurin 53 Ann Rheum Dis 53 MEK Inhibitor 53 PERSEUS 53 Obstet Gynecol 53 Psychopharmacol 53 ORMD 53 Carotid Endarterectomy 53 THERAPEUTICS 53 Soc Sci Med 53 Decompensated Heart Failure 53 Psychiatry #:#-# [001] 53 CLL8 53 AIR CF1 53 HCV NS5B polymerase 53 Myocardial Infarction 53 Percutaneous Transluminal Coronary Angioplasty 53 UMR CNRS 53 Metabolic Efficiency 53 Outpatient Setting 53 lucinactant 53 Multicentre 53 Clin Trials 53 Protein Kinase 53 WEB OF SCIENCE 53 Cochrane Database Syst Rev 53 J Acquir Immune Defic 53 COPERNICUS 53 TAXUS Element Paclitaxel Eluting 53 Br J Haematol 53 pegylated liposomal doxorubicin 53 Gentamicin Surgical Implant 53 THE ORLANDO FLA. 53 Unfractionated Heparin 53 Halozyme Ultrafast Insulin 53 BRILINTA 53 undergoing elective percutaneous 53 ceftazidime 53 Cell Adhesion 53 R#/MEM # 53 Epidermal Growth Factor Receptor 53 Infarct 53 Eluting Coronary Stent System 53 Oxidative Stress 53 Arimidex Tamoxifen Alone 53 Zemplar Capsules 53 Prodrug 53 acute peripheral arterial 53 Randomized Trials 53 Spine Patient Outcomes 53 pharmacokinetic PK 53 篇 53 J Appl 53 Brain Metastases 53 考研 英语 53 Genz # 53 Phase IIIb study 53 HuMax EGFr 53 Critical Reviews 53 EDEMA3 53 Polymorphism 53 Phase III ThermoDox 53 LUMINATE 53 #:#-#,# [003] 53 Kidney Int 53 Clinical Trials Update 53 #mins #.#secs M 53 Sensipar R 53 Article PubMed ChemPort 53 prospective observational 53 #.#mg/kg [002] 53 Curaxin CBLC# 53 Phase 2b Trial 53 peripheral arterial occlusive disease 53 Tocilizumab 53 unfractionated heparin UFH 53 Phase #b/#a clinical 53 entitled Synergistic 53 #:#-# [010] 53 英文 53 J Pathol 53 Metastatic Melanoma 53 daily subcutaneous injections 53 depsipeptide 53 orally administered inhibitor 53 Renal Physiol 53 RISKS UNCERTAINTIES AND ASSUMPTIONS 53 XIENCE V Everolimus Eluting 53 Quinamed 53 Immunol 53 Epratuzumab 53 Prospective Randomized Trial 53 HGS# 53 phase IIb trial 53 MERLIN TIMI 53 Neurosurg 53 relapsed MM 53 J Rheumatol 53 Motility 53 JAK Inhibitor 53 MGd 53 Teijin Pharma 53 transcranial Doppler ultrasound 53 RenalGuard System TM 53 Valsartan 53 BRAHMS 53 HNRCA 53 CCX# B 53 Refractory Angina 53 Hemodialysis Patients 53 BRIM2 53 5 FU leucovorin 53 BRIM3 53 intravesical infusion therapy 53 Antitumor activity 53 prucalopride 53 Surgical Treatment 53 NAVISTAR R 53 Dalbavancin 53 surgically resected 53 samarium Sm 53 PERSEUS clinical program 53 Genetic Variation 53 Arthritis Rheum 53 Spinal Fluid 53 Achieves Primary Endpoint 53 Metastatic Renal Cell Carcinoma 53 Crit Care Med 53 KTM +#:#.# 53 EnteroMedics proprietary neuroblocking technology 53 Am J Physiol 53 HALTS 53 BioNumerik 53 을 53 metastatic malignant 53 CHEAP ONLINE PHARMACY LOW 53 Diamyd Medical Diamyd 53 Fabry Disease 53 Orthop Surg 53 Clinical Psychopharmacology 53 PFO migraine 53 Phase IIb Clinical Trial 53 BOLDER II 53 Randomized Placebo Controlled 53 TAXUS Liberte Long 53 Multicenter Randomized Double 53 nadolol 53 ALLEGRO 53 Traficet EN 53 Melphalan 53 Archexin 53 Sports Exerc 53 Nephrol Dial Transplant 53 수 53 Renal Cell Carcinoma 53 J Foot Ankle 53 Phase IIA 53 CBLC# 53 Alagebrium 53 Solution XOPENEX HFA 53 ThermoDox R 53 Pre RELAX AHF 53 J Biol Chem 53 GetGoal Phase III 53 vs. Angiography 53 thorough QTc 53 catheter occlusion 53 multicenter randomized clinical 53 Randomized Controlled 53 abstr 53 HDAC Inhibitor 53 Phase III Psoriasis 53 Molecular Mechanism 53 SGLT2 inhibitor 53 Endovascular Valve Edge 53 dihydrochloride 53 #:# -# [002] 53 PROSTASCINT R 53 EVEREST II 53 与 的 53 ABCSG 53 IN.PACT 53 Zicam Cold Remedy RapidMelts 53 Heart Failure Patients 53 IMPACT DCM 53 GW# [003] 53 Prevalence Worldwide 52 Psychiatry #:#-# [003] 52 controlled multicenter Phase 52 Centre Hospitalier Universitaire 52 Am J Cardiol 52 Int J Radiat Oncol 52 Signaling Pathway 52 trastuzumab Herceptin R 52 #:#-#,# Medline 52 Am J Epidemiol 52 Paroxysmal Nocturnal Hemoglobinuria PNH 52 Bare Metal Stent 52 e# [005] 52 Joint Surg Am 52 ITH Intl 52 Orqis Medical 52 CONQUER OB 52 CLORETAZINE TM VNP#M 52 年 英语 52 Broc Parkes AUS 52 malignant mesothelioma Alfacell 52 suppl #S 52 Peginterferon Alfa 2a 52 NCT# ClinicalTrials.gov 52 Severe Asthma 52 Placebo Controlled Study 52 Sibutramine Cardiovascular Outcomes 52 Cytometry 52 aneurysms AAA 52 WINS STAGE 52 du Climat et 52 Randomized 52 ThermoDox ® clinical 52 MOTOGP +#.# [001] 52 Progenitor Cells 52 Cerebril TM 52 SPIRIT FIRST 52 Newly Diagnosed Multiple Myeloma 52 ORACLE MS 52 Sirolimus eluting 52 TAXUS TM 52 Blind Placebo Controlled Trial 52 Proteasome 52 treating abdominal aortic 52 外贸 52 Ultrasensitive 52 buccal spray 52 mcg QD 52 Adjuvant Chemotherapy 52 Arch Facial Plast 52 Mucosal Immunology 52 selective A2A adenosine receptor 52 J Natl Cancer Inst 52 Cannabinoid 52 FOLFIRI chemotherapy 52 Blood Pressure Monitoring 52 Onc 52 selective androgen receptor modulator 52 AEG# 52 Systemic Lupus Erythematosus 52 Child Adolesc Psychiatry 52 #:# -# [005] 52 의 에 52 IS NOT SUITABLE FOR 52 #:#-# [024] 52 Epithelium 52 Subaru WRC +# mins 52 Psychol 52 Phase III confirmatory 52 Studien 52 non valvular atrial 52 JOYCE FANG 52 PHOSPHATE 52 Oncol 52 sorafenib tablets 52 XIENCE TM 52 Osteoporos Int 52 ADP receptor antagonist 52 IL# PE#QQR 52 BMC Musculoskeletal Disorders 52 Lung Cancer Trial 52 Ridaforolimus 52 prospective multicenter 52 Predict Risk 52 s# s# 52 部分 52 Intracellular 52 Transcriptome 52 Phase #/#a 52 5RTI 52 Thrombotic 52 PDE4 inhibitor 52 Lymphocytic 52 LEVAQUIN ® 52 Formoterol 52 ROCKET AF 52 Syllego system 52 J Gerontol 52 更多 的 52 ON TWITTER AND 52 J Shoulder Elbow 52 double blinded placebo 52 Institut de Recherche 52 Kinase Inhibitors 52 Cogn 52 randomized multicenter 52 Raloxifene Evaluation MORE 52 DEB# 52 Der Videopodcast Die 52 Factor VIIa 52 SUCCEED trial 52 Randomized Phase III 52 chimeric monoclonal antibody 52 Abstract Full Text 52 Neurosci 52 Venous Thromboembolism 52 Phys Ther 52 solifenacin succinate 52 et de Biologie 52 de Recherche Clinique 52 Am J Geriatr 52 Adenoviral 52 Phase III randomized 52 Current Controlled Trials 52 吗 52 IFN α 52 Cytochrome P# 52 Evo IX +# mins 52 Regul Integr Comp Physiol 52 ALN VSP Phase 52 Cochrane Database Syst Rev. 52 Vascular Inflammation 52 Tesmilifene 52 AA Amyloidosis 52 Cardiovascular Interventions 52 Oral Mucositis 52 Atrasentan 52 Clinical Physiology 52 口语 52 Sleep Disturbances 52 Plasmin 52 inhaled AAT 52 #mg QD [002] 52 Collategene 52 PRICE GREAT DISCOUNT FREE 52 R bendamustine hydrochloride 52 Biol 52 Renal Cancer 52 Betaferon R 52 Tumor Response 52 J Orthop 52 或者 52 近 52 suppl 52 CABG Surgery 52 Patency 52 E1 INT TM 52 occlusion PAO 52 Fracture Intervention Trial 52 Oral Presentation 52 prospective randomized placebo 52 PROTECT AF 52 Arno Therapeutics 52 REGEN trial 52 Pediatr 52 SABCS 52 Aptivus ® 52 Cardiovasc 52 Relieve Depression 52 Mouse Model 52 BCIRG 52 IIIa inhibitor 52 Suppl 52 Oncogene 52 Truvada tablets 52 Acute Liver Failure 52 Granulocyte Colony Stimulating Factor 52 PRTX 52 PLoS Genet 52 MAGE A3 ASCI 52 Biochem Pharmacol 52 DOI #.#/science.# 52 Ar dheis Dé 52 HCV RESPOND 2 52 paroxysmal nocturnal hemoglobinuria 52 2mins #.#s 52 PATENT FOR 52 Rheumatol 52 #:# randomization 52 Embolic Protection Device 52 PRE SURGE 52 Nipent R 52 R# #mg BID 52 beta 1a 52 KEVIN LIM 51 Physiology Seminar 51 riociguat 51 AND DEVELOPMENT OF 51 Miner Res 51 Thrombolysis 51 OPTIMIZE 51 First Patient Enrolled 51 CIMZIA TM certolizumab pegol 51 Sign Licensing Agreement 51 TG MV 51 에 을 51 acute PAO 51 NGFN 51 Seikagaku Corporation 51 Multaq R 51 Neovascularization 51 的 和 51 Demineralized Bone Matrix 51 J Affect Disord 51 APTIVUS 51 Lowers Risk 51 Hepatocellular 51 PRoFESS 51 NN# [001] 51 翻译 51 Nebulized 51 Invasive Fungal Infections 51 Medizin 51 Piano Op 51 MYDICAR ® 51 Teplizumab 51 Pharmacokinetics 51 Onrigin TM 51 D Minor Op 51 LENALIDOMIDE 51 Preclinical Efficacy 51 CLARITY study 51 Human Hookworm Vaccine Initiative 51 Nippon Shinyaku 51 CIMZIA TM 51 Suzuki GSX R #K# 51 Captopril 51 RGOODMAN@ENQUIRER.COM 51 ORAL Solo 51 CAPRIE 51 Nonalcoholic Steatohepatitis 51 Classical Vocal Performance 51 Randomized Comparison 51 과 51 elotuzumab 51 Mstislav Rostropovich conductor 51 Psychiatry #:#-# [002] 51 docetaxel Taxotere ® 51 Diabetes Interventions 51 By Yang Lifei 51 sitagliptin phosphate 51 ARCOXIA 51 Solid Tumors 51 postmenopausal osteoporotic women 51 이 을 51 C Minor Op 51 #.#secs A8 51 TRIAL OF 51 ATL/TV# 51 Serostim ® 51 nab paclitaxel 51 Hematol 51 Pitavastatin 51 targeting miR 51 Female Urology 51 Trial PCPT 51 의 을 51 AMCG DEST FISH HUDV 51 Smooth Muscle 51 Adjuvant Therapy 51 Recherche et 51 Aprilia +#:#.# 51 Preclinical Models 51 Apaziquone 51 Cell Biol 51 fully bioabsorbable 51 By SHELBY G. 51 Pivotal Clinical Trial 51 第 51 Non Alcoholic Steatohepatitis 51 somatostatin analogue 51 J Clin Invest 51 Zenvia ™ 51 ENDEAVOR clinical 51 Genome Res 51 Mol Psychiatry 51 阅读 51 Clin Pharmacol Ther 51 Cinacalcet HCl 51 prospective multicenter randomized 51 Antisense Oligonucleotides 51 Recurrent Glioblastoma 51 Sym# 51 By AKILAH IMANI 51 Endeavor Drug Eluting 51 SEAMLESS 51 Ibritumomab Tiuxetan 51 Acute Myocardial 51 doxorubicin cyclophosphamide 51 TROPIC 51 candidate CRLX# 51 menaquinone 51 ST Segment Elevation 51 DNA Methylation 51 Luveniq 51 BEST TO DESCRIBE 51 PROMUS Element Stent 51 Levels Linked 51 Randomized Controlled Trial 51 Phase Ib study 51 PET FROM 51 J Cataract Refract 51 HQK 51 Tolerability Study 51 DAPT 51 #:#-# [018] 51 Recurrent Breast Cancer 51 Phase IIa Evidence 51 PG Andersson Suzuki WRT 51 Article PubMed 51 Arch Dis Child 51 Succinate 51 blind multicenter 51 Embolic 51 Dent Res 51 doi #.#/S#-#